These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 9145428

  • 1. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
    Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, Robberecht P.
    Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
    [Abstract] [Full Text] [Related]

  • 2. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P, Rathé J, De Neef P, Cnudde J, Vandermeers-Piret MC, Waelbroeck M, Robberecht P.
    Eur J Pharmacol; 1998 Jul 31; 354(1):105-11. PubMed ID: 9726637
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V, Kienlen-Campard P, Loeffler JP, Basille M, Gonzalez BJ, Vaudry H, Robberecht P, Pévet P.
    Neuroscience; 1998 Aug 31; 85(3):887-96. PubMed ID: 9639281
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J, Gourlet P, De Neef P, Robberecht P, Waelbroeck M.
    Mol Pharmacol; 1996 Dec 31; 50(6):1596-604. PubMed ID: 8967982
    [Abstract] [Full Text] [Related]

  • 11. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
    Vertongen P, Delhase M, Rajas F, Trouillas J, Hooghe-Peters E, Svoboda M, Robberecht P.
    J Mol Endocrinol; 1996 Jun 31; 16(3):239-48. PubMed ID: 8782082
    [Abstract] [Full Text] [Related]

  • 12. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
    Van Rampelbergh J, Poloczek P, Françoys I, Delporte C, Winand J, Robberecht P, Waelbroeck M.
    Biochim Biophys Acta; 1997 Jun 27; 1357(2):249-55. PubMed ID: 9223629
    [Abstract] [Full Text] [Related]

  • 13. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
    Gourlet P, Vilardaga JP, De Neef P, Vandermeers A, Waelbroeck M, Bollen A, Robberecht P.
    Eur J Biochem; 1996 Jul 15; 239(2):349-55. PubMed ID: 8706739
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG, De Neef P, Robberecht P.
    Prostate; 1999 Sep 15; 41(1):1-6. PubMed ID: 10440869
    [Abstract] [Full Text] [Related]

  • 17. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
    Vertongen P, Camby I, Darro F, Kiss R, Robberecht P.
    Neuropeptides; 1996 Oct 15; 30(5):491-6. PubMed ID: 8923513
    [Abstract] [Full Text] [Related]

  • 18. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H.
    Endocrinology; 1999 Mar 15; 140(3):1285-93. PubMed ID: 10067855
    [Abstract] [Full Text] [Related]

  • 19. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
    Uchida D, Tatsuno I, Tanaka T, Hirai A, Saito Y, Moro O, Tajima M.
    Ann N Y Acad Sci; 1998 Dec 11; 865():253-8. PubMed ID: 9928019
    [Abstract] [Full Text] [Related]

  • 20. Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy.
    Gourlet P, Vandermeers A, Vandermeers-Piret MC, De Neef P, Robberecht P.
    Int J Pept Protein Res; 1996 Oct 11; 48(4):391-6. PubMed ID: 8919060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.